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Abstract 
To clarify the role of protein tyrosine phosphatase contaimng Src homology 2 (SH2) regions on insulin signaling, we investigated the interactions 
among the insulin receptor, a pair of SH2 domains of SH-PTP2 coupled to glutathione-S-transferase (GST) and insulin receptor substrate-l 
(IRS-I)-GST fusion proteins (amino-portion, IRS-IN; carboxyl portion, IRS-1C). GST-SH2 protein of SH-PTP2 bound to the wild type insulin 
receptor, but not to that with a carboxyl-terminal mutation (YIF2). Furthermore, even though Y/F2 receptors were used, the SH2 protein was also 
co-immunoprecipitated with IRS-IC, but not with IRS-IN. These results indicate that SH2 domains of SH-PTP2 can directly associate with the 
Y’322TXM motif on the carboxyl terminus of insulin receptors and also may bind to the carboxyl portion of IRS-I, possibly via the Y”“IDL motif 
in vitro. 
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1. Introduction 
Protein tyrosine phosphorylation states are regulated 
by both protein tyrosine kinase (PTK) and protein tyro- 
sine phosphatase (PTPase) and are thought to be one of 
the crucial steps for the regulation of cell growth, differ- 
entiation and metabolism [1,2]. Activation of growth fac- 
tor receptors results in the autophosphorylation of tyro- 
sine residues in the cytoplasmic regions of the receptors. 
Subsequent ransmission of the ligand-induced signal is 
thought to be dependent on the recognition of the phos- 
phorylated tyrosine (phosphotyrosine motifs) by distinc- 
tive domains, known as the SH2 (Src homology 2) region 
[3.4]. Insulin receptor autophosphorylation stimulates 
*Corresponding author. Fax: (81) (775) 43 3858. 
Abbreviations: SH2, Src homology 2; IRS-l. insulin receptor substrate- 
1; IRS-IN, amino-portion of IRS-1 (amino acids 434764); IRS-1C. 
carboxyl-portion of IRS-l (amino acids 1132-1235); GST. glutathione- 
S-transferase; Y/F2. a mutant receptor in which both carboxyl-terminal 
tyrosine residues (13 16 and 1322) are replaced by phenylalanine; PTK, 
protein tyrosine kinase; PTPase. protein tyrosine phosphatase; PtdIns 
3’-kinase, phosphatidylinositol 3’-kinase: WGA, wheat germ aggluti- 
nin; HIRc cells, Rat 1 fibroblasts expressed with human insulin recep- 
tors: a IR, anti-insulin receptor antiserum; cc GST, anti-GST antiserum: 
PCR. polymerase chain reaction; PDGF, platelet-derived growth factor. 
receptor PTK, and the autophosphorylation induces the 
association of insulin receptors with PTPase containing 
SH2 regions [5], possibly via the motif on the carboxyl 
terminus (Y’3’2THM) [6,7]. On the other hand, insulin 
receptor substrate- 1 (IRS- 1) contains multiple potential 
tyrosine phosphorylation sites, and tyrosine-phosphory- 
lated IRS-I binds to phosphatidylinositol (PtdIns) 3’- 
kinase and GRB2, suggesting that the IRS-l employs a 
discrete SH2-docking protein [8-l 31. 
Several types of novel non-transmembrane PTPases 
which contain a single phosphatase domain and two ad- 
jacent copies of SH2 regions at its amino terminus have 
been reported [14-211. Thus, it is speculated that the 
activation of PTK is regulated by the PTPase via an 
SH2 domain-mediated interaction with tyrosine-phos- 
phorylated receptors. Therefore, we investigated the in- 
teractions between a pair of SH2 domains of PTPases 
(SH-PTP2, PTPlC) and insulin receptors to clarify the 
role of PTPases containing the SH2 region on insulin 
signaling. We found that the GST-SH2 protein of SH- 
PTP2, but not that of PTPlC, may associate with the 
carboxyl-terminus of insulin receptors [5]. 
To clarify the significance of this PTPase in insulin 
signaling, we further identified not only a putative bind- 
ing site of SH2 protein in the carboxyl terminus of insulin 
receptors, but also a possible binding site for IRS-1 with 
this SH-PTP2. 
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(Y/F21 insulin receptors (500 fmol insulin binding capacity) were incu- 
bated with GST-SH2 orotein (25 ua) of SH-PTP2 in the nresence of 100 
PM ATP ([Y-~‘P]ATP: 30 &i/tube) for 3 h at 4°C and these proteins 
were then immunoprecipitated by antibodies (a IR and a GST) and 
resolved by SDS-PAGE. 
2.1. Materials 
Restriction endonucleases and modifying enzymes were purchased 
from Takara Shuzo and Toyobo. Recombinant Taq polymerase was 
obtained from Perkin-Elmer Cetus. Oligonucleotide primers were syn- 
thesized on an Applied Biosystem 380A synthesizer. The vector pGEX- 
3X and wheat germ agglutinin (WGA) agarose were obtained from 
Pharmacia PL Biochemical Co. Purified porcine insulin was a gift from 
Novo-Nordisk Pharmar Ltd. ‘*’ I- labeled procine insulin at Al4 (A14- 
[‘251]insulin; 2200 Ci/mmol) was obtained from New England Nuclear. 
[Y-~~P]ATP was purchased from Amersham International pk. Anti- 
insulin receptor antiserum (cc IR) was obtained from a Type B insulin 
resistant patient with Sjdgren’s syndrome as previously described [22]. 
Rat 1 fibroblasts stably over-expressed human insulin receptors (HIRc) 
and the expression vector for carboxyl-terminal mutant insulin recep- 
tors (cvsvHIRY/F2) in which both carboxyl-terminal tyrosine residues 
(1316 and 1322) were replaced by phenylalanine, were previously de- 
scribed [23,24]. COS 7 cells and the transient expression vector for 
human insulin receptor (pGEM3SVHIR) were gifts from Dr. H. 
Teraoka (Shionogi Research Laboratory, Osaka, Japan) [25]. All other 
reagents were of analytical grade from Sigma, Bio-Rad and Nakarai 
Chemical Co. 
2.2. Cell culture 
Both HIRc and COS 7 cells were maintained in Dulbecco’s modified 
Eagle’s medium containing 10% fetal calf serum. 
2.3. Polymerase chain reaction (PCR) and subcloning of the cDNA for 
IRS-1 
Rat liver genomic DNA was isolated by the standard methods. PCR 
primers for IRS-1 were designed to amplify the regions that contained 
the 1st to 6th YMXM (YXXM) motifs at the amino terminus (amino 
acids 434-764, 993 bp from ref. [8], designated IRS-lN), and the car- 
boxy1 terminus (amino acids 1132-1235, 312 bp; IRS-1C). PCR pro- 
ceeded in an air thermal cycler (Idaho model 1620) for 30 cycles (94°C 
for 10 s. 55°C for 20 s and 72°C for 40 s). The PCR nroducts were 
subcloned into sequence vectors (pUCl18,i 19) and the pGEX-3X ex- 
pression vector with restriction enzyme (EcoRI and BamHI) cleavage 
sequences attached to the PCR primers. Nucleotide sequences of sub- 
cloned DNA were determined using an automated laser fluorescent 
sequencer (Pharmacia). 
2.4. Purification of GSTfusion proteins 
SH2 protein of SH-PTP2 coupled to GST was synthesized by PCR 
as previously described [5]. Bacterial GST fusion-proteins were ob- 
tained bv the recommended nrotocol. GST-SHZSH-PTP2. GST-IRS- 
1N and GST-IRS-1C were purified using affinity column chromatogra- 
phy. GST-SH2 protein of SHPTP2 was cleaved by factor X (Takara), 
then the SH2 protein of SH-PTP2 (23 kDa) was purified. An anti-rabbit 
GST polyclonal antiserum (a GST) was raised by the standard method, 
and this antibody immunoprecipitated more than 90% of the GST 
fusion proteins (GST-SHZSH-PTP2, GST-IRS-IN and GST-IRS-1C) 
under our experimental conditions (data not shown). 
2.5. Purification of insulin receptors and preparation of the carboxyl- 
terminal truncated and mutated insulin receptors 
Insulin receptors were partially purified using WGA from HIRc cells 
and [‘ZSI]insulin binding to purified receptors was assessed using poly- 
ethylene glycol as previouslv described 123.261. Accordina to the 
method of Goren et-al. [27], the 85-kDa carboxyl-terminal tyuncated 
insulin receptors were prepared by trypsin digestion (lO@ml for 1 min 
at 22°C). The pGEM3SV-HIRY/F2 expression plasmid was con- 
structed by replacing the BglI-SpeI fragment of the insulin receptor 
cDNA of pGEM3SVHIR with that of the cvsvHIRY/F2 plasmid. Car- 
boxyl-terminal mutated (YIF2) insulin receptors which lost the 
Y’3ZtTXM motif at the carboxyl terminus were obtained from COS 7 
cells transfected with the pGEM3SV_HIRY/F2 plasmid using DEAE- 
dextran [25]. 
2.6. Phosphorylation ofSH2 protein of PTPase by Inszdzn receptor 
kznase 
After incubating insulin receptors with 167 nM insulin for 16 h, 
normal, carboxyl-terminal truncated and carboxyl-terminal mutated 
2.7. Interaction of SH2 protein of PTPase and GST-IRS-l fusion 
proteins 
We next examined the association of SH2 protein with 
phosphorylated GST-IRS-l fusion proteins (GST-IRS-IN and GST- 
IRS-1C) as well as insulin receptors. After insulin stimulation, GST- 
IRS-l fusion proteins (20 pg) were phosphorylated by either wild type 
or mutant insulin receptor (500 fmol insulin binding capacity) in the 
presence of 100 PM ATP ([r-“P]ATP, 30~ Ci/tube) for 3 h at 4’C. 
GST-uncoupled SH2 protein (30 ,ug) of SH-PTP2 was added into this 
mixture containing receptor and IRS-l and incubated for a further 3 h 
at 4°C. These proteins were immunoprecipitated with antibody 
(a GST) then resolved to SDS-PAGE. 
3. Results 
We studied whether the putative binding site for SH2 
protein was Y’322THM at the carboxyl terminus of insu- 
lin receptors. We found that wild-type insulin receptors 
phosphorylated the GST-SH2 protein of SH-PTP2 and 
were co-immunoprepitated with this SH2 protein by 
GST antiserum. On the other hand, the carboxyl-termi- 
nal-truncated insulin receptors failed to associate with 
SH2 protein, suggesting that the SH2 domains of SH- 
PTP2 associate with the carboxyl terminus of insulin 
receptors. Furthermore, the carboxyl-terminal-mutated 
(Y/F2) insulin receptors, where this motif in the carboxyl 
terminus was destroyed by replacing tyrosine residues 
with phenylalanine, phosphorylated GST-SH2 protein, 
but failed to associate with the SH2 protein, as did the 
carboxyl-terminal truncated insulin receptors (Fig. 1). 
These results indicate that the SH2 protein of SH-PTP2 
binds to Y1322TXM motif at the carboxyl terminus of 
insulin receptors. 
To assess whether this SH2 protein of SH-PTP2 bound 
to IRS-l, and if so, where the putative binding site of 
SH2 protein was located in IRS- 1, we constructed GST- 
IRS-1 fusion proteins (GST-IRS-1N and GST-IRS-lC), 
and studied the association of these GST-IRS-1 proteins 
with GST-uncoupled SH2 protein of SHPTP2. Phos- 
phorylated SH2 protein co-immunoprecipitated with 
GST-IRS- 1 C, but GST-IRS-1N was not affected by anti- 
GST antibody, suggesting that the phosphorylated GST- 
IRS-1N failed to bind to SH2 protein of SH-PTP2, but 
GST-IRS-1C bound to SH2 protein in vitro. Insulin re- 
ceptor kinase phosphorylated GST-IRS-1N to a lesser 
extent than GST-IRS-IC under our experimental condi- 
tions. Thus, we used the more phosphorylated GST-IRS- 
1N protein. However, there was no evident association 
of GST-IRS-1 with the SH2 protein (data not shown). 
It remained possible that SH2 protein co-immunoprecip- 
itated with IRS-l proteins via the interaction of the car- 
boxy1 terminus of the insulin receptor. To rule this out, 
we used the carboxyl-terminal-mutated (Y/F2) receptor 
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Wild Type C-terminal C-terminal 
truncated mutated (Y/F2) 
Ir----ll-----l 
4 IR b Truncated IR /3 
4 GST-SH2 
antibody alfl aGST NS alI3 aGST NS all3 aGST 
Fig. 1. Phosphorylation of the SH2 domains of PTPase by insulin receptor kinase and association of SH2 domains with the autophosphorylated 
carboxyl-terminus of the insulin receptor. After insulin stimulation, normal (wild-type), carboxyl-terminal-truncated, and carboxyl-terminal-mutated 
(YIF2) insulin receptors were incubated with GST-SH2 fusion protein (SO kDa) in the presence of 100 PM ATP at 4°C for 3 h, then these proteins 
were immunoprecipitated with anti-insulin receptor antiserum (CC IR). anti-GST antiserum (a GST), and normal serum (NS), respectively and resolved 
by SDS-PAGE. 
instead of the wild-type in these association studies. The 
SH2 protein was co-immunoprecipitated with GST-IRS- 
1C as shown in Fig. 2. These results suggest hat the 
binding site for SH-PTP2 lies on the Y1’721DL motif on 
the carboxyl terminus of the IRS-1 molecule. 
These findings suggest hat the SH2 protein of SH- 
PTP2 can be phosphorylated by insulin receptor PTK 
and associate with insulin receptors via its Y13*‘TXM 
motif on the carboxyl terminus of insulin receptors. 
However, several putative phosphotyrosine motifs 
(YMXM or YXXM) on the amino-terminus of IRS-l 
cannot associate with SH2 domains. On the other hand, 
the YIDL motif on the carboxyl terminus of IRS-l may 
bind to SH2 domains of this PTPase. 
4. Discussion 
Activated growth factor receptor PTK stimulates 
intracellular signaling pathways by binding to and phos- 
phorylating regulatory cytoplasmic protein with phos- 
photyrosine motifs. It has been reported that PTPases 
homologous to SH-PTP2 can be phosphorylated in the 
cells stimulated by either platelet derived growth factor 
(PDGF) or by epidermal growth factor [20,21]. Further- 
more, SH-PTP2 is phosphorylated at the tyrosine resi- 
dues and directly binds to these growth factor receptors 
[2gl. 
Even though the insulin receptor has a phosphoty- 
rosine motif on the carboxyl-terminal (Y’322THM) [6,7], 
there is no evidence that its autophosphorylation induces 
association with a signal protein containing SH2 regions. 
However, we recently found that a pair of SH2 domains 
of SH-PTP2 are phosphorylated by insulin receptor PTK 
and that the insulin receptors are co-immunoprecipitated 
with GST-SH2 protein OS SH-PTP2 by anti-GST antise- 
rum, suggesting that SH2 domains of SH-PTP2 directly 
IRS-1 N IRS-1 N IRS-1C 
+ IRS-1 c 
4 GST-IRS-1N 
SH2 Protein (-) (+) (+) 
Fig. 2. Association of phosphorylated GST-IRS-l fusion proteins with 
GST-uncoupled SH2 protein of SH-PTPZ. After insulin stimulation, 
carboxyl-terminal-mutated (Y/F2) msulin receptors and GST-IRS-I 
fusion proteins (GST-IRS-IN, and GST-IRS-lC, 20 pg each) were 
incubated in the presence of 100 ,uM ATP at 4°C for 3 h. GST-uncou- 
pled SH2 protein (23 kDa) was then added to the mixture and incubated 
for a further 3 h. These proteins were immunoprecipitated with anti- 
GST antiserum (01 GST), and resolved by SDS-PAGE. 
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associate with insulin receptors [5]. In this study, we also 
found that the carboxyl-terminal-truncated and car- 
boxyl-terminal-mutated Y/F2 insulin receptors 
phosphorylated SH2 protein, but could not bind to it, 
indicating that the YTXM motif at 1322 on the carboxyl 
terminus of the insulin receptor is a binding site for the 
SH2 domains of SH-PTP2. Based upon the peptide bind- 
ing analysis of growth factor receptors such as PDGF 
receptors, Y(I/V)X(VIIILIP) motifs are putative binding 
sites for the N-terminal SH2 domain of SH-PTP2 [29]. 
However, the Y’O”9TXV motif of the PDGF j? receptor 
is the binding site of SH-PTP2 and it is speculated that 
the binding site of SH-PTP2 is a Y (hydrophobic/neutral 
amino acid) X V motif in vivo [30]. The phosphotyrosine 
motif at the carboxyl terminus of the insulin receptor is 
YTXM, which is similar to the YTXV motif in the 
PDGF receptor. 
When the insulin receptor becomes activated, it phos- 
phorylates IRS-l on numerous tyrosine residues within 
seconds. IRS-l may function as a docking protein, bring- 
ing various component proteins to the insulin signaling 
pathway [8-131. For SH-PTP2, it is still unclear whether 
IRS-l plays the role of a docking protein like PtdIns3’- 
kinase and GRB2. Syp, the mouse counterpart of SH- 
PTP2 co-immunoprecipitates with IRS-l [31]. However, 
the binding site(s) of SH-PTP2 for IRS-l remains un- 
clear. According to a peptide binding study [29], the 
Y895VNI and Y’17’IDL motifs may be the putative bind- 
ing sites for SH-PTP2 in IRS-l. In this study, we found 
that the carboxyl-portion of IRS-1 that contained the 
Y117*IDL motif, bound to the SH2 protein. It is still 
unclear whether the Y8g5VNI motif is the binding site for 
SH-PTP2. Furthermore, IRS-1C also contains a putative 
tyrosine phosphorylation site at Y’222ASI as well as at 
Y’17*IDL. However, the Y ‘***AS1 motif is not consistent 
with the possible binding motifs as previously reported. 
To identify the exact binding motif for SH-PTP2 of the 
carboxyl-terminus of IRS-l, further studies using the 
IRS-1 mutants, where these possible binding motifs are 
destroyed, are now going to be investigated in our labo- 
ratory. On the other hand, the amino-portion of IRS-l 
containing the 1st to 6th YXXM motifs failed to bind to 
SH2 protein. With regard to these differences in the 
phosphotyrosine motifs of various proteins for the bind- 
ing of SH2 protein of SH-PTP2 (YIDL and YTXM), it 
has been suggested that the N-terminal SH2 domain of 
SH-PTP2 is least selective compared with other SH2 
regions [29]. Therefore, the SH2 domains of SH-PTP2 
may bind to the other motifs such as the YTXM in 
addition to the YIDL motif in the carboxyl portion of 
IRS- 1. Alternatively, the tertiary structure of the binding 
site surrounding these motifs may be an important deter- 
minant of the binding affinity for SH2 domains of this 
PTPase as well as phosphotyrosine motifs of the amino 
acid residues. 
SH-PTP2 mRNA is widely distributed throughout the 
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body, including insulin-sensitive tissues such as liver and 
skeletal muscles, and PTPases homologous to SH-PTP2 
have little or no effect on the phosphorylation state of 
the insulin receptor PTK, although the expression of 
PTPlC leads to the dephosphorylation of receptor PTK 
including insulin receptors [21]. However, it is still un- 
known whether SH-PTP2 can dephosphorylate tyrosine 
phosphorylated IRS-l. In this study, we demonstrated 
that SH-PTP2 is phosphorylated by insulin receptor ki- 
nase and it is associated with the Y’322TXM motif on the 
carboxyl terminus of the insulin receptor. Simultane- 
ously, it may also bind to the Y”‘*IDL motif on the 
carboxyl terminus of IRS-l. This association of SH- 
PTP2 with either insulin receptor or IRS-l may modu- 
late a phosphorylationdephosphorylation cascade of 
insulin action. 
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